Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453818 | 0.84 | ALDH1A1 (0.64) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA | |
| SCHEMBL10162702 | 0.83 | ALDH1A1 (0.71) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA | |
| SCHEMBL23781564 | 0.80 | ALDH1A1 (0.71) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA | |
| SCHEMBL372200 | 0.80 | ALDH1A1 (1.00) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA | |
| SCHEMBL12603967 | 0.78 | ALDH1A1 (0.64) | ALDH1A1ACACBCYP1A2TLR8 | |
| SCHEMBL547195 | 0.78 | ALDH1A1 (0.59) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA | |
| SCHEMBL27614825 | 0.78 | ALDH1A1 (0.59) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA | |
| SCHEMBL7214768 | 0.77 | ALDH1A1 (0.63) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA | |
| SCHEMBL8907669 | 0.77 | ALDH1A1 (0.77) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA | |
| SCHEMBL14294117 | 0.77 | ALDH1A1 (0.62) | ALDH1A1ACACBCYP1A2PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-8063021-B2 | Ketolide anti-infective compounds | KOSAN BIOSCIENCES INCORPORATED (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2008061189-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7247617-B2 | Sixteen-member macrolide antiinfective agents | KOSAN BIOSCIENCES INCORPORATED (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247617-B2 | Sixteen-member macrolide antiinfective agents | KOSAN BIOSCIENCES INCORPORATED (US) | 2007-07-24 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | ALDH1A1 452/4885ACACB 428/4885CYP1A2 104/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | ALDH1A1 452/4885ACACB 428/4885CYP1A2 104/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | ALDH1A1 452/4885ACACB 428/4885CYP1A2 104/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | ALDH1A1 732/4885ACACB 771/4885CYP1A2 117/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | ALDH1A1 1193/4885ACACB 1127/4885CYP1A2 59/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | ALDH1A1 353/4885ACACB 1676/4885CYP1A2 38/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | ALDH1A1 452/4885ACACB 428/4885CYP1A2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.